Mauro Carta
Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic
Mugheddu, CristinaPrimo
Data Curation
;Dell'Antonia, MassimoSecondo
Writing – Original Draft Preparation
;Sanna, SilviaMembro del Collaboration Group
;Agosta, DanieleMembro del Collaboration Group
;Atzori, Laura
Penultimo
Writing – Review & Editing
;Rongioletti, FrancoUltimo
Supervision
2020-01-01
Abstract
Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from care givers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.File | Dimensione | Formato | |
---|---|---|---|
guselkumab cornelia covid.pdf accesso aperto
Tipologia: versione post-print
Dimensione 1.96 MB
Formato Adobe PDF
|
1.96 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.